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ABSTRACT: Monoamine oxidases (MAO) are FAD-containing flavoenzymes that catalyze the degradation of a 
range of brain neurotransmitters, whose imbalance is extensively linked with the pathology of various 
neurological disorders. This is why MAOs have been the central pharmacological targets in treating 
neurodegeneration for more than 60 years. Still, despite this practical importance, the precise chemical 
mechanisms underlying the irreversible inhibition of the MAO B isoform with clinical drugs rasagiline (RAS) and 
selegiline (SEL) remained unknown. Here we employed a combination of MD simulations, MM–GBSA binding 
free energy evaluations, and QM cluster calculations to show the MAO inactivation proceeds in three steps, 
where, in the rate-limiting first step, FAD utilizes its N5 atom to abstracts a hydride anion from the inhibitor α-
CH2 group to ultimately give the final inhibitor-FAD adduct matching crystallographic data. The obtained free 
energy profiles reveal a lower activation energy for SEL by 1.2 kcal mol–1 and a higher reaction exergonicity by 
0.8 kcal mol–1, the former in excellent agreement with experimental ΔΔG‡EXP = 1.7 kcal mol
–1, thus rationalizing 
its higher in vivo reactivity over RAS. The calculated ΔGBIND energies confirm SEL binds better due to its bigger 
size and flexibility allowing it to optimize hydrophobic C–H···π and π···π interactions with residues throughout 
both of enzyme's cavities, particularly with FAD, Gln206 and four active site tyrosines, thus overcoming a larger 
ability of RAS to form hydrogen bonds that only position it in less reactive orientations for the hydride 
abstraction. Offered results elucidate structural determinants affecting the affinity and rates of the inhibition 
reaction that should be considered to co-operate when designing more effective compounds devoid of untoward 
effects, which are of utmost significance and urgency with the growing prevalence of brain diseases. 
KEYWORDS: irreversible inhibition, monoamine oxidase, hydride transfer, antiparkinsonian drugs, 
neurodegeneration, flavoenzymes   
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INTRODUCTION 
Monoamine oxidase (MAO) is a flavin adenine dinucleotide (FAD)-containing enzyme that metabolizes a range 
of biogenic and dietary amines, as well as monoamine neurotransmitters, such as dopamine, serotonin and 
adrenaline, in both the central nervous system and peripheral tissues.1 The rapid degradation of these molecules 
ensures the proper functioning of synaptic neurotransmission and is critically important for the regulation of brain 
functions. Since monoaminergic signaling is regarded as one of the key mechanisms for the modulation of mood 
and emotion, as well as the control of motor, perceptual and cognitive functions, any imbalance in the 
concentration of these neurotransmitters in the brain has been identified in most, if not all, neuropsychiatric and 
neurological diseases.  
MAO exists in two known and fully characterized isoforms, namely MAO A and MAO B,2 which share 
around 70% sequence identity and the same FAD co-factor (Figure 1) covalently attached at a conserved cysteine 
residue.3 Their deep active site cavities are different in volume and shape4 conferring very different substrate and 
inhibitor specificities.5 The chemical reaction catalyzed by MAO involves the oxidation of the amine moiety via 
oxidative cleavage of the substrate α-CH bond with the ensuing generation of an imine intermediate. This 
pathway is accomplished by the reduction of FAD to FADH2 that is reoxidized back to FAD by molecular 
oxygen, with simultaneous hydrogen peroxide release. Later, the imine intermediate is hydrolyzed by a non-
enzymatic pathway yielding the related aldehyde and either ammonia (with primary amines) or a substituted 
amine (from secondary amines),5 according to the overall equation:  
 
As such, the byproducts of MAO-mediated reactions include a number of potentially neurotoxic agents.6–8 
Consequently, a prolonged excessive activity of MAO enzymes may be conducive to mitochondrial damages and 
neurodegenerative disturbances. In keeping with these premises, the progress in MAO inhibition has led to 
important breakthroughs in the therapy of several psychiatric and neurological diseases, ranging from mood 
disorders to Parkinson (PD) and Alzheimer diseases (AD).9 Furthermore, the characterization of MAO knockout 
mice10 has revealed that the inactivation of this enzyme produces a number of functional and behavioral 
alterations, some of which may be harnessed for therapeutic aims. The modulation of brain and behavior by MAO 
inhibitors11 has, therefore, made the design of new inhibitors a medicinal chemistry challenge in both academia 
and industry for the last 60 years.12   
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Figure 1. Chemical structures of systems discussed in this work together with the relevant atom numbering. 
 
The development of MAO inhibitors started with the non-selective reversible inhibitors ipronazid and 
phenelzine,13 yet these were shown to be associated with diverse adverse effects, including liver toxicity14 and the 
so-called "cheese reaction", consisting in severe, potentially lethal hypertensive crises following the consumption 
of foods rich in tyramine,15 which prompted research to characterize selective inhibitors. Since tyramine oxidation 
occurs exclusively by intestinal MAO A, selective MAO B inhibitors, such as selegiline (SEL) and rasagiline 
(RAS), revealed that these were efficacious for the PD treatment, yet being free from this potential interaction, 
which warrants their use without the restriction of a low-tyramine diet.16 Inhibiting MAO B not only prolongs the 
half-life of dopamine and extends its neurotransmission effect for relieving motor symptoms, it also prevents the 
MAO B-mediated oxidative damages during dopamine degradation,17 which is further prompted by the fact that 
more than 80% of MAO in the human brain is of the B subtype.18 Yet, the anti-MAO B drugs are still linked with 
significant untoward effects,19 and treat only the symptoms of a disease not the cause, which underlines the 
necessity for the design of new and more potent compounds.  
The majority of MAO inhibitors in current use are mechanism-based irreversible inhibitors,9,20 whose activity 
relies on forming a covalent bond with the enzyme, which is the most successful way of inhibiting MAO B in 
vivo.21 Selegiline (L-deprenyl, SEL) was the first such irreversible drugs to be clinically used and has been on the 
market since the late 1980s.22 Its adduct with N5 on FAD (Figure 1) has been identified both chemically23 and in 
the crystal structure of MAO B.24 However, SEL is metabolized to L-amphetamine-like metabolites which can 
cause appetite suppression and insomnia.25 In addition, amphetamines inhibit dopamine's transport to vesicles,26a–b 
making it susceptible to the autooxidation in the cytoplasm,26c giving rise to the additional source of the reactive 
oxygen species. As a safer alternative, in the first decade of this century the propargyl analogue rasagiline (RAS) 
was developed and approved, which features the same mechanism of action.27 Unlike SEL, RAS does not give 
amphetamine-like metabolites and is devoid of the neurotoxic side effects of the other drug, while its major 
metabolite 1-aminoindan is also neuroprotective,28 allowing a lower daily dose, which is all why it is more widely 
used nowadays. In general, the clinical practice confirmed that propargylamine MAO B inhibitors are effective 
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and safe medications that provide symptomatic benefit for Parkinson patients from early to late stages of 
disease.29   
Today, there is a broad spectrum of therapeutic possibilities for the utilization of MAO inhibitors. Novel routes 
of administration, as well as pro-drugs which are converted to active inhibitors by brain enzymes, are promising 
directions for future progress. Research efforts over last years offered many classes of potent and more selective 
compounds,30–32 as well as understanding structural determinants affecting the selectivity among isoforms.33 
However, for a rational prediction of more effective systems, what is seriously missing are details of a precise 
chemical mechanism of the inhibition reaction. This would make path for a design of mechanism-based drugs as 
transition-state analogues that are likely to improve the selectivity and efficacy in neurodegenerative diseases, 
which might consent the use of lower therapeutic doses, thus strongly diminishing possible adverse effects. To 
address this point, in this work we carried out molecular dynamics simulations34 to investigate the binding of SEL 
and RAS within the MAO B active site and underline residues predominantly responsible for the successful 
binding. This is followed by QM cluster calculations35 at the DFT level to elucidate, to the best of our knowledge, 
for the first time in the literature, the exact mechanism leading from bound inhibitors to the corresponding 
N5(FAD)-adducts (Figure 1).  
 
RESULTS AND DISCUSSION 
Molecular Dynamics Simulations. Molecular dynamics simulations were performed to inspect the 
conformational flexibility of RAS and SEL within the MAO B active site, and to reveal specific interactions 
governing the binding (full computational details are given in the Supporting Information). The calculated binding 
free energies, ΔGBIND, for both inhibitors are presented in Table 1 together with their decomposition into 
contributions from individual residues. Illustrative snapshots from MD trajectories are shown in Figure 2.  
It turns out ΔGBIND for both inhibitors are negative and indicate favorable binding. Yet, the value for SEL is 
more exergonic, showing it is better positioned within the active site, being in line with a trend in the measured Ki 
and IC50 values (Table 1). It is noteworthy that our ΔGBIND energies appear in good qualitative agreement with 
those by Mangiatordi et al.,33 who reported data between –13 and –22 kcal mol–1 for the two reversible chromene 
MAO inhibitors, although the obtained ΔGBIND(SEL) = –31.83 and ΔGBIND(RAS) = –28.36 kcal mol
–1 are likely 
overestimated in absolute terms. This is a known limitation of the MM-GBSA approach, as extensively discussed 
in a recent review by Homeyer et al.,36 which also underlined its huge potential in predicting relative binding 
energies in the biomolecular complexes.36 In this context, even more importantly than absolute values, the 
difference between the calculated ΔGBIND is 3.5 kcal mol
–1 in favor of SEL. To put this number in a proper 
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perspective, let us mention that, although Ki and IC50 for irreversible inhibitors are not solely mirroring the 
binding of the inhibitors alone, they give useful insight into relative binding trends. As such, it is gratifying to see 
that measured values predict SEL to bind better by 2.5 kcal mol–1 (from Ki) and 2.6 kcal mol
–1 (from IC50), which 
puts our results in a rather good agreement with experiments and lends credence to the presented conclusions.  
 
Table 1. Calculated binding free energies (ΔGBIND) from molecular dynamics trajectories using MM-GBSA 
approach, and their decomposition on a per-residue basis (in kcal mol–1).a Graphical representation is given in 
Figure S1. The obtained values are compared with available experiments. 
inhibitor RAS SEL 
ΔGBIND –28.36 –31.83 
FAD –2.94 –3.26
Gln206 –2.53 –2.59
Tyr435 –0.87 –1.39
Tyr398 –1.73 –1.25
Leu171 –0.56 –0.91
Tyr60 –0.71 –0.60
Cys172 –0.18 –0.52
Phe343 –0.82 –0.51
Ile198 –0.05 –0.51
Gly434 –0.15 –0.38
Leu328 –0.41 –0.35
Tyr326 –0.55 –0.32
Thr399 –0.07 –0.21
Val173 –0.04 –0.18
Gly205 –0.09 –0.18
Met341 –0.14 –0.16
Gln191 –0.04 –0.13
Arg42 –0.01 –0.11
Tyr188 –0.03 –0.11
Ile199 –0.94 –0.10
Ser59 –0.10 –0.10
Ki(h-MAO B) 700 nM
b 9 nMc 
IC50(h-MAO B) 82.5 nM
d 1.3 nMe
aResidues are selected to list all of those with contributions higher than –0.10 kcal mol–1 for SEL and these 
account for around half of the total binding for both inhibitors. A broader analysis in presented as Table S1 in the 
Supporting Information. bFrom ref. 37. cFrom ref. 38. dFrom ref. 39. eFrom ref. 40.  
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Further analysis of MD trajectories and the decomposition of ΔGBIND values into contributions from specific 
residues provide some clues to why SEL binds better. Table 1 shows that both inhibitors are primarily stabilized 
by interacting with FAD, which accounts for around 10% of the total binding energies. This is established through 
favorable π···π interactions among the aromatic rings on FAD and inhibitors acetylene groups, which are mainly 
responsible for positioning inhibitors in reactive conformations. Interestingly, with its acidic N–H group, RAS 
forms hydrogen bonding with the carbonyl C(4)=O group on FAD. This is persistent through the entire MD 
simulation (Figure S2) with the average N(RAS)–O(FAD) distance of 3.427 Å, yet the overall interaction with 
FAD is lower. In SEL, this position is N-methylated, which then prevents hydrogen bonding with the co-factor 
and results in its farther distance from FAD in the enzyme-inhibitor complex (Figure S3). Yet, it will turn out (see 
later) that this RAS–FAD hydrogen bonding, in addition to lowering the binding, exerts a negative effect on the 
reactivity as well. Furthermore, RAS can act both as a donor and acceptor of the hydrogen bonding with active 
site residues, which permit it to interact with, for example, the –OH groups in tyrosines. On the other hand, SEL 
can only act as a hydrogen bond acceptor, yet even this ability is sterically hindered with the present N-methyl 
group. As a result, RAS forms hydrogen bonds around four times more frequently than SEL (0.8 vs. 0.2 hydrogen 
bonds per each ns of the MD simulation, respectively, Figure S4), yet its overall binding is lower. This strongly 
underlines that the capacity of inhibitors to form hydrogen bonds within the active site is not primarily responsible 
for the affinity, but other electrostatic and hydrophobic interactions are dominating in this respect. Therefore, our 
results indicate that, for a successful design of novel inhibitors, it is likely beneficial to have a tertiary instead of a 
secondary amino group within the structure.  
             
Figure 2. Representative structures of irreversible inhibitors selegiline (SEL, left) and rasagiline (RAS, right) 
placed within the MAO B active site as obtained from the MD simulations. 
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Interestingly, among amino acid residues, both inhibitors are mostly stabilized by Gln206 achieved by its side 
chain –NH2 group interacting with aromatic fragments on inhibitors through favorable N–H···π interactions 
(Figure S5). This fact emphasizes the significance of aromatic moieties in the design of more potent compounds, 
which promote the binding within the hydrophobic active site.41 Tyrosines Tyr435 and Tyr398 were identified 
both experimentally42 and computationally41,43 as important in properly orienting substrates for the chemical 
reaction, and their mutations have led to enzymes with considerably reduced activities.44 Analogously, it turned 
out that these residues are also significant for the inhibitor affinity (Figure 2), together with other active site 
tyrosines, Tyr60 and Tyr326 (Figure S6), and one phenylalanine residue Phe343. Unlike hydrogen bonding, SEL 
is more efficient in interacting with aromatic residues, as evidenced in its higher propensity to interact with four 
active site tyrosines (Figure S6), by making around 0.50 such contacts per each ns of the MD simulation, as 
opposed to 0.34 contacts that RAS forms. This is strongly in line with Geha et al.,45 who demonstrated that IC50 
for SEL is increased 15 and 130 times upon Tyr398Phe and Tyr435Phe mutations. In addition, SEL is clearly a 
more flexible molecule, with more rotatable bonds, allowing it to assume such conformations to optimize contacts 
with other hydrophobic residues as well, such as Leu171, Cys172 and Gly434. Lastly, what is particularly 
interesting are inhibitors’ interactions with Ile199, since this residue was experimentally proposed as the "gating 
residue" in MAO B,46 supported by recent calculations,43 in some studies together with Tyr326.47 Notably, Ile199 
is conserved in all known MAO B sequences except bovine MAO B, which has Phe in this position that is, in 
turn, a conserved residue in the analogous position in MAO A. It is demonstrated that in a "closed conformation", 
Ile199 separates hydrophobic entrance and substrate cavities in MAO B thus producing a bipartite active site 
configuration, while its "open conformation" allows the fusion of both cavities to a large total volume of ~700 Å3, 
much larger than a monopartite substrate cavity of ~550 Å3 in MAO A, and a successful substrate or inhibitor 
binding.46 Since SEL is larger and more elongated than RAS, it pushes both Ile199 and Tyr326 to adopt an "open 
conformation", which creates a cavity big enough to accommodate SEL and diminishes their interactions (Table 
1), as already observed in all human MAO B crystal structures in complex with bulky inhibitors.24b Still, this 
change within the enzyme enhances the overall binding of SEL, which now includes interactions with residues 
from both cavities, matching observations that MAO B displays an increase in the binding affinity for systems 
that bridge both cavities.47 On the other hand, RAS is a more compact molecule than SEL and smaller 
conformational changes in the cavities are required for its binding, which promotes its interactions with both 
Ile199 and Tyr326, being as large as –0.94 and –0.55 kcal mol–1, respectively. This is fully in line with 
crystallographic analysis revealing that RAS snugly fits into the substrate cavity alone, and that Ile199 is in 
contact with its benzene moiety.48 This notion is also strongly supported by the fact that for a very small inhibitor 
isatin, the Ki value is increased four times upon Ile199Ala mutation and more than 100-fold in the Ile199Ala-
Tyr326Ala double MAO B mutant.47 Taken all together, these results further underline a critical role of Ile199 
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and Tyr326 in determining inhibitor binding specificity for MAO B, and strongly indicate that aromatic and 
hydrophobic interactions are promoting the binding.  
In summarizing this section, the obtained results confirm that SEL is a better binder primarily because it is a 
more flexible molecule being able to adjust its hydrophobic interactions with active site residues throughout both 
cavities, thus overcoming a better propensity of RAS to both accept and donate hydrogen bonds. As the calculated 
relative binding energies and found in very good agreement with experiments, this insight provides the first step 
in designing more effective MAO B inhibitors.  
 
Quantum Chemical Analysis of the Inhibition Reaction. Although the initial discovery of mammalian MAOs 
was published 90 years ago,49,50 and despite the fact that their inhibitors, reversible and irreversible, equipotent on 
both isoforms or highly selective, have been used for more than 60 years for the treatment of various neurological 
disturbances,12 the precise molecular mechanism by which irreversible inhibitors form the N5 adduct with FAD 
and, thereby, suppress MAO's further catalytic activity has remained unknown. A possible reason for that 
becomes evident by looking at the adduct structure (Figure 1). Namely, apart from creating a chemical bond with 
N5(FAD), the inhibitor must undergo a 1,2-hydrogen shift from C(α) to C(β) to allow the final product. This 
suggests this is not a simple reaction and it certainly involves more than one step. To address this question, 
following MD simulations, we created a cluster model of MAO B with both RAS and SEL, including the FAD 
co-factor and Tyr435, Tyr398, Tyr326, Tyr188, Ile199, Lys296, Cys172 and Gln206 residues, together with three 
active site water molecules, as described in the Supporting Information. M06–2X/6–31+G(d,p) geometry 
optimization gave stationary points corresponding to enzyme-inhibitor complexes (Figure 2).  
Initially, we first tried to model a direct C(γ)inhibitor–N5(FAD) bond forming reaction starting with neutral 
inactivated inhibitors. This reaction probes the electrophilic character of the co-factor's N5 atom and its 
propensity to attack the inhibitor π-system. Taking SEL as an example, with unionized Lys296 the reaction is 
favorable (ΔGr = –19.8 kcal mol
–1) and the formed adduct is stable and characterized with the C(γ)–N5 distance 
of 1.430 Å. However, this reaction is associated with a very high barrier of 47.8 kcal mol–1, which makes it 
unlikely. In the case of a monoprotonated Lys296, the reaction becomes even endergonic (ΔGr = 4.9 kcal mol
–1) 
while maintaining the barrier height. A similar magnitude of values is obtained with RAS as well. All of this 
suggests that the inhibition process does not follow this mechanism.  
Secondly, we assumed that inhibitors get activated by terminal C(γ)–H deprotonation. In the absence of basic 
active-site residues to perform the proton abstraction,51 we modeled a direct inhibitor deprotonation by N1 on 
FAD (Figure 1). This was prompted by the vicinity of these two centers (5.505 Å for SEL, and 3.327 Å for RAS), 
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and the fact that N1 is the most basic position on FAD.52 This is further supported by the NBO charges on N1, –
0.64 |e| for both inhibitors in the reactants. Yet, the obtained products, the N1-protonated FAD and a deprotonated 
inhibitor are much less stable than initial systems, having ΔGr = 30.6 kcal mol
–1 for SEL with unionized Lys296 
and ΔGr = 23.0 kcal mol
–1 with ionized Lys296. Such high energy requirements are rationalized by a large 
difference in the pKa values between proton donor and acceptor sites. For the flavin N1–H deprotonation this was 
measured to be around 7.0,53 whereas acetylene deprotonation typically has a pKa of around 25,
54 and can be 
achieved only by very strong superbases.54  
Recently, we performed the first QM study that demonstrated the prevailing feasibility of the direct hydride 
transfer mechanism over several alternative pathways for the catalytic dopamine degradation using a similar 
cluster model of MAO B.52 This was later extended by considering the full enzyme dimensionality through the 
empirical valence bond QM/MM approach,55 which gave the activation free energy of 16.1 kcal mol–1, being in 
excellent agreement with the experimentally determined value of 16.5 kcal mol–1,24b thus supporting the proposed 
mechanism. Latter, we expanded our work to a range of other substrates and MAO A isoform as well,43,56 and all 
of the results agree well with experiments employing the mechanism in which the hydride anion is transferred 
from the substrate's C(α) atom to N5(FAD) in the rate-limiting first step. Our mechanistic picture is gaining some 
affirmation in the literature,57 and is fully corroborated by very recent 13C kinetic isotope effect measurements on 
a related polyamine oxidase flavoenzyme.58 For those reasons, we deemed it worthwhile to employ this 
mechanism in understanding the inhibition reaction, particularly since it is established that both RAS and SEL are 
mechanism-based irreversible inhibitors.9,20   
Optimization of initial geometries gave stationary points (SP1, Figure 3) where both inhibitors are properly 
oriented for the hydride abstraction. As already discussed, because of its acidic N–H group, RAS is positioned 
closer to FAD, contrary to SEL that features the N-methyl moiety which prevents a shorter proximity. In SP1, the 
corresponding N5(FAD)–C(α) distances are 3.523 Å for RAS and 4.386 Å for SEL. These are found in excellent 
agreement with average values of 3.669 and 4.223 Å obtained after MD simulations (Figure S3), which strongly 
supports the selection of representative MD snapshots for the subsequent quantum-mechanical analysis.  
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Figure 3. Free-energy profiles for the irreversible MAO B inhibition with rasagiline (RAS) and selegiline (SEL). 
Initial rate-limiting step involves a direct hydride anion transfer from the methylene C(α) atom onto the N5 atom 
of the FAD co-factor. Acronyms SP and TS indicate stationary points and transition states, respectively, and their 
chemical structures are depicted in Figure 4.  
 
Direct α–hydride abstraction turned out feasible in both inhibitors (Figure 3), in agreement with our results for 
the MAO catalysis.43,52,55,56 In the transition state TS1, the transferring hydrogen is placed between the leaving α–
carbon and the accepting N5 atom, with the bond distances of 1.408 and 1.268 Å for RAS, respectively, being 
somewhat more symmetrical in SEL at 1.410 and 1.280 Å, in the same order. Despite these similarities, the 
activation free energy for this process in SEL is 27.9 kcal mol–1 (νimag = 1243i cm
–1), which is increased to 29.1 
kcal mol–1 in RAS (νimag = 1213i cm
–1). Since this is the rate-limiting step of the overall transformation (Figure 3), 
these values deserve some further comments. Interestingly, this trend in the reactivity, which predicts SEL to 
react more efficiently, is fully in line with the determined kinact values of 0.99 min
–1 for SEL59 and 0.0533 min–1 
for RAS.60 Even more so, these experimental parameters translate to a difference in the activation free energy of 
1.7 kcal mol–1 in favor of SEL, which is excellently matched by our calculations of 1.2 kcal mol–1 here (Figure 3) 
that lends strong credence to our results.  
A possible explanation for a lower reactivity of RAS is offered by considering geometric parameters within the 
active site. Namely, in addition to its lower flexibility, the hydrogen bonding that RAS makes with both FAD and 
neighboring residues locks it in a position in which it is less prepared for the H– abstraction. Specifically, the 
distribution of relevant angles N5(FAD)···H–C(α)  for both methylene hydrogens in SEL is such that there is 
always one H-atom with the angle close to 0° (Figure S7) that is optimal for the H– transfer. In this way SEL is 
able to more successfully optimize its position for the reaction with FAD. In contrast, RAS is more rigid and only 
one of its methylene hydrogens can undergo the hydride abstraction. Furthermore, through electron-donation, the 
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additional amino N-methyl group in SEL provides extra stabilization to the positive charge created upon the H– 
abstraction, an effect absent in RAS. To illustrate that, our calculations on isolated inhibitors show that it is by 7.6 
kcal mol–1 easier to strip H– from C(α) in SEL than it is in RAS, a result dominated by the presence of the 
electron donating methyl group on the vicinal amino nitrogen.  
 
 
Figure 4. Chemical structures corresponding to stationary points (SP) and transition states (TS) during the 
irreversible MAO inhibition reaction in the most feasible hydride transfer mechanism, in accordance with free 
energy profiles shown in Figure 3.  
 
The fact that this process is indeed associated with the transfer of a hydride anion is evident in the atomic NBO 
charges and relevant bond distances. Here, we are presenting results for SEL (Table 2), while the corresponding 
data for RAS are found in Table S2, being similar and offering same conclusions. Initially, total charges on SEL 
and FAD in SP1 are 0.01 and 0.03 |e|, respectively, to be altered to 0.36 and –0.36 |e| in TS1. This indicates that 
during the reaction SEL loses around one third of an electron that is afterwards accommodated on FAD. In 
addition, the charge on the accepting N5(FAD) changes from –0.36 |e| in SP1 to –0.51 |e| in TS1. Interestingly, 
the charge on the inhibitor C(α) atom, from which the H– anion is abstracted, changes only moderately from 0.26 
to 0.37 |e|, which is rationalized by the presence of the neighboring amino group that compensates the charge loss 
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through electron donation. This is seen in the reduced charge on the amino nitrogen and the shortened N(amino)–
C(α) distance, changing from –0.54 |e| and 1.473 Å in SP1 to –0.48 |e| and 1.409 Å in TS1, which is all consistent 
with the proposed H– transfer.  
 
Table 2. Charge distribution (NBO analysis, in |e|) and selected bond distances (in Å) during the rate-limiting 
hydride abstraction in the irreversible inhibition reaction with selegiline (SEL) as obtained at the (CPCM)/M06–
2X/6–31+G(d,p) level.  
System 
Atom/Bond/ 
Molecule 
Isolated 
Enzyme-
Inhibitor 
Complex (SP1) 
Transition 
State (TS1) 
Intermediate 
(SP2) 
 
Namino –0.52 –0.54 –0.48 –0.50 
C(Namino) –0.50 –0.50 –0.50 –0.50 
α–H 0.24 0.26 0.37 0.46 
α–C –0.34 –0.35 –0.24 –0.04 
β–C –0.04 –0.03 –0.04 –0.06 
γ–C –0.25 –0.27 –0.27 –0.31 
SEL 0.00 0.01 0.36 0.51 
N–C(methyl) 1.462 1.467 1.464 1.464 
N–C(α) 1.466 1.473 1.409 1.395 
C(α)–C(β) 1.469 1.468 1.403 1.320 
C(β)–C(γ) 1.205 1.207 1.234 1.307 
 
N5 –0.34 –0.36 –0.51 –0.68 
C4a 0.09 0.10 0.05 –0.01 
C10a 0.45 0.45 0.48 0.54 
N1 –0.65 –0.64 –0.65 –0.65 
FAD  0.00 0.03 –0.36 –0.54 
N(5)–C(4a) 1.291 1.290 1.336 1.434 
C(4a)–C(10a) 1.461 1.458 1.455 1.515 
C(10a)–N(1) 1.307 1.306 1.310 1.302 
 
Initial hydride transfer is exergonic, ΔGr = –9.8 kcal mol
–1 for SEL and ΔGr = –8.5 kcal mol
–1 for RAS, and 
creates a negatively charged FADH– and a positively charged inhibitor. This is shown in the charge distribution, 
as the full formation of a new N5–H– bond increases the charge on FAD to –0.54 |e|, while the charge on SEL 
becomes 0.51 |e|. Such electrostatic difference leads to a spontaneous adduct formation SP2 (Figure 4), where the 
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inhibitor C(γ) atom binds to C4a on FAD. The formed adduct is rather strong, as evidenced in short C(γ)–C4a 
bonds of 1.555 Å for SEL and 1.545 Å for RAS. Moreover, the calculated adduct dissociation energies are ΔGdiss 
= 31.1 kcal mol–1 for SEL and ΔGdiss = 36.3 kcal mol
–1 for RAS, which confirm their strong nature. Yet, despite 
their stability, the reaction proceeds further as the following stationary points are found even lower in energy than 
SP2. Binding to FAD creates an allene-type motif within inhibitors (SP2, Figure 4) as evidenced in an even 
distribution of C(α)–C(β) and C(β)–C(γ) bonds of 1.320 and 1.307 Å in SEL, and 1.315 and 1.306 Å in RAS. In 
allene, the most reactive/nucleophilic is the middle C(β) atom,61 so the next step involves the transfer of the 
abstracted hydrogen from N5(FAD) onto C(β) as a proton H+, as seen in the charge within SEL that changes from 
0.51 |e| in SP2 to 0.73 |e| in TS2. An analogous transfer to C(γ) is not feasible, while that to C(α) reverts the 
system back to SP1. The mentioned N5–H···C(β) proton transfer is associated with barriers of 17.6 kcal mol–1 for 
SEL (νimag = 1075i cm
–1) and 18.0 kcal mol–1 for RAS (νimag = 1283i cm
–1), which are smaller than those for the 
initial H– abstraction. This creates SP3, which features the formation of a strained three-membered ring among 
N5 and C4a on FAD and C(γ) on an inhibitor (Figure 4), yet it is further lower in energy, likely because of the 
instability of the allene structure in the confined environment of the preceding SP2. The corresponding N5–C(γ), 
N5–C4a and C4a–C(γ) distances are 1.465, 1.452 and 1.537 Å for SEL, while 1.468, 1.454 and 1.530 Å for RAS, 
respectively. Although strained, SP3 is more stable than SP2, likely due to the instability of an allene in this 
confined environment. Interestingly, the reaction leading to SP3 is more exergonic for RAS, although it will turn 
out that the overall thermodynamic profile is more favorable for SEL (Figure 3).  
The last step involves the breaking of the bond between C(γ)inhibitor–C4a(FAD) and the formation of a full 
C(γ)–N5(FAD) bond as in SP4. In TS3, the former are already much elongated to 1.929 Å (SEL) and 1.820 Å 
(RAS), while the process is linked with barriers of 6.4 kcal mol–1 for SEL (νimag = 305i cm
–1) and 5.4 kcal mol–1 
for RAS (νimag = 383i cm
–1), being the smallest along the profile. This step is highly exergonic and leads to final 
products. Specifically, in RAS the end product is stabilized by 25.3 kcal mol–1 to a final ΔGr = –38.3 kcal mol
–1. 
This is even more pronounced in SEL, which benefits from 33.8 kcal mol–1 stabilization to give ΔGr = –39.1 kcal 
mol–1. The electronic structure of adduct is complex, and it involves a positive charge delocalized within the 
conjugated inhibitor cyanine chain. Most of the excess positive charge is located within the N(amino) and C(α) 
atoms that gain 0.18 and 0.49 |e| relative to SP1, while the bond connecting these two atoms is shortened by 0.05 
Å (Table 3). The conjugated scaffold was also confirmed by a very recent computational analysis of a hindered 
rotation about both pairs of C–N and C–C bonds within a model system.62 Moreover, the geometry of the final 
adduct is in very good agreement with available X-ray structures (Table 3). Interestingly, in SP4, FAD features an 
anionic N1 atom with the NBO charge of –0.67 |e|, being consistent with very recent mass spectrometry data that 
revealed a deprotonated nature of the N1 site in the adduct even under fairly acidic experimental conditions (pH ≈ 
2).62   
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Table 3. Charge distribution (in |e|) and selected bond distances (in Å) in the N5(FAD) adducts with selegiline 
and rasagiline. Comparison is done with available crystal structures.  
Structure Bond/Atom Selegiline Adduct 2BYB.pdb Rasagiline Adduct 1S2Q.pdb
 
N5–C(γ) 1.329 1.28 1.331 1.28 
C(γ)–C(β) 1.387 1.33 1.383 1.29 
C(β)–C(α) 1.398 1.52 1.394 1.53 
C(α)–N(amino) 1.315 1.47 1.311 1.29 
N5–C4a 1.420 1.39 1.419 1.38 
C4a–C10a 1.404 1.41 1.398 1.39 
C10a–N1 1.326 1.38 1.332 1.39 
N5 –0.36  –0.36  
C(γ) 0.14  0.13  
C(β) –0.48  –0.44  
C(α) 0.15  0.15  
N(amino) –0.37  –0.56  
C4a –0.14  –0.14  
C10a 0.47  0.46  
N1 –0.67  –0.71  
 
In finishing this section, it is worth to emphasize that the revealed mechanism is feasible as it proceeds 
downhill in energy with high exergonicity of the overall transformation and the rate-limiting hydride abstraction. 
It also confirms experimental observations that both SEL and RAS are mechanism-based irreversible 
inhibitors,9,20 while the obtained free-energy profiles rationalize the higher reactivity of SEL from both the lower 
activation free-energy ΔΔG‡ = 1.2 kcal mol–1 and a more pronounced exergonicity ΔΔGr = 0.8 kcal mol
–1. To 
further strengthen our conclusion, let us mention that we excluded the possibility of the electron-transfer 
mechanism, in which an inhibitor is activated by transferring an electron to FAD, a process that was considered 
for the MAO catalysis.63 Our model gave the following ionization free energies, IE(SEL) = 134.5 kcal mol–1 and 
IE(RAS) = 146.1 kcal mol–1, which are not matched by the calculated electron affinity EA(FAD) = –77.2 kcal 
mol–1. Such a large energy mismatch suggests electron transfer to FAD is highly implausible and we did not 
consider it further. In addition, the calculated free-energy profiles involving the ionized active-site Lys296 residue 
(Figure S8) show investigated reactions are less favorable than those already presented for the neutral Lys296. In 
this way, these results parallel those we obtained for the MAO catalytic activity, where the MAO B dopamine 
degradation proceeds with unionized Lys296,55 and confirm it is very likely this residue has an active role only in 
16 
 
activating the molecular oxygen and facilitating the regeneration of FADH2 to FAD, and not in the catalytic 
transformation of substrates or in the inhibition reaction, as already speculated in the literature.64  
 
CONCLUSIONS 
While there have been no revolutionary treatments for Parkinson and Alzheimer diseases in the last few 
decades, great interest remains in the development of new drugs, novel delivery systems, and drug combinations, 
which are of utmost importance with the growing prevalence of these illnesses. MAO B inhibitors are widely used 
in the management of both diseases and a variety of other psychiatric disorders, and continue to be investigated 
for their therapeutic value and disease-modifying potential. 
Here we used a combination of MD simulations, MM–GBSA binding free energy evaluations, and QM cluster 
calculations to elucidate the precise molecular mechanism behind the irreversible MAO inhibition with 
propargylamine drugs, and rationalize higher reactivity of selegiline (SEL) over rasagiline (RAS) that are both in 
the clinical use. We showed the MAO inactivation proceeds through a three-step reaction, where, in the rate-
limiting first step, the enzyme uses the N5 atom on its FAD co-factor to abstract a hydride anion from the 
inhibitor's α-CH2 group, being in full analogy with the MAO catalytic mechanism, thus confirming both SEL and 
RAS are mechanism-based inhibitors. The initial hydride abstraction creates a C4a(FAD) adduct and an allene-
motif in the inhibitor, which proceeds by transferring the N5-hydrogen back to the inhibitor's C(β) atom, which 
then forms a three-membered ring with C(γ), and N5 and C4a atoms on FAD. The last step involves the breaking 
of a bond with the C4a atom and the formation of the N5-adduct, thus nicely tying in with the crystallographic 
structures. The obtained reaction profiles reveal that the overall process is both kinetically and thermodynamically 
more favorable for SEL, as its activation energy is lower by ΔΔG‡ = 1.2 kcal mol–1 and the reaction is more 
exergonic by ΔΔGr = 0.8 kcal mol
–1. Both of these support the fact SEL is a more potent inhibitor as evidenced in 
the measured kinact values, which predicts a difference of ΔΔG
‡
EXP = 1.7 kcal mol
–1, hence putting our results in 
excellent agreement with experiments. Let us also mention that it remains a challenge to experimentally confirm 
the anionic nature of the inhibitor-FAD transferring hydrogen during the inhibition. As possible routes to achieve 
that, one could turn to structure-relation studies with a series of modified compounds, or utilize kinetic 
measurements with isotopically labeled inhibitors,58 and their realization is strongly recommended. In addition, 
we hope these results will also stimulate further computational efforts that should, among other things, evaluate 
the influence of the whole enzyme environment and potential mutations on the inhibition reaction. Although our 
extensive experience with QM cluster calculations suggests this is unlikely to change the presented mechanistic 
conclusions,41,43,52,55,56 this is a welcome task, since a very recent report65 underlined the importance of residues 
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beyond the immediate vicinity of the active site in determining the catalytic power of the MAO A isoform, and 
signified the likely decisive role of electrostatics in the enzymatic reactions.  
The higher reactivity of SEL is further promoted by several contributions. SEL is larger and a more flexible 
molecule, so it assumes elongated active-site conformations that allow it to stretch and maximize interactions with 
residues from both MAO cavities, yielding a higher ΔGBIND(SEL) = –31.83 kcal mol
–1. In contrast, RAS is a 
more rigid and compact system binding only within a substrate cavity closer to FAD. This leads to more 
pronounced interactions with the "gating" Ile199 and Tyr326 residues, yet the overall binding is lower at 
ΔGBIND(RAS) = –28.36 kcal mol
–1, being in line with measured Ki and IC50 data. In addition, RAS has a 
secondary amine N–H group that can both donate and accept hydrogen bonds, which is not the case with SEL that 
features an N-methyl group. Indeed, our results revealed RAS is around four times more frequent in forming 
hydrogen bonds within the active site, yet these only position it in less reactive orientations for the subsequent H– 
abstraction. What is responsible for better binding of SEL are hydrophobic C–H···π and π···π interactions, 
particularly with four active site tyrosines and FAD, and favorable N–H···π interactions with Gln206 that was 
identified as the most dominant residue in the SEL binding.  
Taken all together, the computational insight presented here suggests that, for a future design of more potent 
irreversible MAO inhibitors, one should look for long flexible molecules with aromatic fragments or other 
moieties rich in π-electrons, which would be able to stretch and optimize hydrophobic interactions with residues 
within both of enzymes cavities. Also, tertiary amines are more likely to assume reactive conformations than 
secondary analogues, while additionally providing a stabilizing electron-donating effect with its N-alkyl group 
during the rate-limiting H– abstraction reaction. Also, given the residual1–3 and electrostatic66 similarities in their 
active sites and overall structures, this insight could turn beneficial for the design of MAO A inhibitors as well, 
that are clinically employed to treat various forms of depression.12   
The increase of MAO B activity in ageing brain resulting in increased oxidative stress suggests that the hunt 
for new effective brain-targeted MAO B inhibitors will continue. Although new reversible inhibitors have been 
proposed, there is no indication that they will be successful in vivo. By being the first to demonstrate the 
prevailing feasibility of the hydride transfer mechanism for the inhibition reaction, we provided mechanistic 
insight for the action of traditional irreversible inhibitors that are effective and now better understood drugs. It is 
reasonable to expect that the results offered here should open the door towards designing more effective MAO 
inhibitors as transition-state analogues devoid of adverse effects. This is particularly important since mechanism-
based inhibitors provide the most specific type of inhibitors, because the enzyme has not only to recognize and 
bind the inhibitor; it also has to perform a part of its normal catalytic function to generate an activated species that 
then reacts with the enzyme. This means that there are, at least, two factors to be optimized to obtain high 
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selectivity and potency – the affinity of the enzyme for the non-covalent inhibitor binding and the rates of the 
subsequent steps leading to the irreversible inactivation. These two factors should ideally co-operate, where a 
higher binding affinity is further enhanced by a higher reactivity to give the adduct. Hopefully, our computational 
results could guide in both directions.  
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